{"nctId":"NCT00706849","briefTitle":"Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease","startDateStruct":{"date":"2008-07"},"conditions":["Heterozygous Familial Hypercholesterolemia","Coronary Artery Disease"],"count":124,"armGroups":[{"label":"Mipomersen","type":"EXPERIMENTAL","interventionNames":["Drug: mipomersen sodium"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"mipomersen sodium","otherNames":["ISIS 301012","Kynamro™"]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of Heterozygous Familial Hypercholesterolemia (HeFH)\n* Diagnosis of Coronary Artery Disease (CAD)\n* Stable lipid-lowering therapy for 12 weeks\n* On maximally tolerated statin therapy with at least 1 statin at a dose greater than zero, per Investigator judgment\n* Stable low-fat diet for 8 weeks\n* Stable weight for 6 weeks\n\nExclusion Criteria:\n\n* Significant health problems in recent past including heart attack, stroke, coronary syndrome, unstable angina, heart failure, significant arrhythmia, orthostatic hypotension, uncontrolled hypertension, blood disorders, liver disease, cancer, or digestive problems\n* Receiving apheresis treatment or last apheresis treatment within 8 weeks","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the Primary Efficacy Time Point","description":"LDL cholesterol was measured in mg/dL. Samples were taken following an overnight fast. For patients with triglycerides \\<400 mg/dL, LDL-C was obtained using Friedewald's calculation; and for patients with triglycerides ≥400 mg/dL, LDL-C was directly measured by the central laboratory using ultracentrifugation. The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.17","spread":"18.02"},{"groupId":"OG001","value":"-28.02","spread":"26.99"}]}]}]},{"type":"PRIMARY","title":"LDL Cholesterol at Baseline and at the Primary Efficacy Time Point","description":"The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"142.9","spread":"51.6"},{"groupId":"OG001","value":"152.9","spread":"48.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"146.4","spread":"43.4"},{"groupId":"OG001","value":"103.9","spread":"33.0"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B at the Primary Efficacy Time Point","description":"Apolipoprotein B was measured in mg/dL. Samples were taken following an overnight fast. The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.02","spread":"16.52"},{"groupId":"OG001","value":"-26.31","spread":"22.16"}]}]}]},{"type":"SECONDARY","title":"Apolipoprotein B at Baseline and at the Primary Efficacy Time Point","description":"The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"126.8","spread":"33.2"},{"groupId":"OG001","value":"132.8","spread":"33.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"133.8","spread":"32.6"},{"groupId":"OG001","value":"95.0","spread":"29.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol at the Primary Efficacy Time Point","description":"Total cholesterol was measured in mg/dL. Samples were taken following an overnight fast. The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.85","spread":"12.84"},{"groupId":"OG001","value":"-19.43","spread":"19.25"}]}]}]},{"type":"SECONDARY","title":"Total Cholesterol at Baseline and at the Primary Efficacy Time Point","description":"The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"213.4","spread":"54.6"},{"groupId":"OG001","value":"225.3","spread":"51.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"219.0","spread":"49.0"},{"groupId":"OG001","value":"176.0","spread":"35.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol at the Primary Efficacy Time Point","description":"Non-high-density lipoprotein cholesterol was measured in mg/dL. Samples were taken following an overnight fast. The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.74","spread":"16.04"},{"groupId":"OG001","value":"-25.05","spread":"25.71"}]}]}]},{"type":"SECONDARY","title":"Non-High-Density Lipoprotein Cholesterol at Baseline and at the Primary Efficacy Time Point","description":"The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"165.3","spread":"54.5"},{"groupId":"OG001","value":"175.5","spread":"51.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"168.2","spread":"47.5"},{"groupId":"OG001","value":"125.2","spread":"37.8"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Triglycerides at the Primary Efficacy Time Point","description":"Triglycerides were measured in mg/dL. Samples were taken following an overnight fast. The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"20.77"},{"groupId":"OG001","value":"-14.3","spread":"43.76"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Triglycerides at Baseline and at the Primary Efficacy Time Point","description":"The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":"53.3"},{"groupId":"OG001","value":"107","spread":"39.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":"42.5"},{"groupId":"OG001","value":"89","spread":"70.1"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Lipoprotein (a) at the Primary Efficacy Time Point","description":"Lipoprotein (a) was measured in mg/dL. Samples were taken following an overnight fast. The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"15.10"},{"groupId":"OG001","value":"-21.1","spread":"24.22"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Lipoprotein (a) at Baseline and at the Primary Efficacy Time Point","description":"The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":"56.2"},{"groupId":"OG001","value":"45","spread":"64.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":"53.5"},{"groupId":"OG001","value":"35","spread":"55.3"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Very Low Density Lipoprotein Cholesterol at the Primary Efficacy Time Point","description":"Very low density lipoprotein (VLDL) cholesterol was measured in mg/dL. Samples were taken following an overnight fast. The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"20.11"},{"groupId":"OG001","value":"-13.8","spread":"45.70"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Very Low Density Lipoprotein at Baseline and at the Primary Efficacy Time Point","description":"The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":"9.5"},{"groupId":"OG001","value":"21","spread":"7.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":"8.5"},{"groupId":"OG001","value":"18","spread":"14.6"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in the Ratio of LDL Cholesterol to HDL Cholesterol at the Primary Efficacy Time Point","description":"The ratio of low-density lipoprotein (LDL) cholesterol to high-density lipoprotein (HDL) cholesterol was measured at Baseline and the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"19.38"},{"groupId":"OG001","value":"-29.2","spread":"29.99"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Ratio of LDL Cholesterol to HDL Cholesterol at Baseline and at the Primary Efficacy Time Point","description":"The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.72","spread":"1.495"},{"groupId":"OG001","value":"2.99","spread":"1.353"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.95","spread":"1.337"},{"groupId":"OG001","value":"2.09","spread":"1.034"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Apolipoprotein A1 at the Primary Efficacy Time Point","description":"Apolipoprotein A1 was measured in mg/dL. Samples were taken following an overnight fast. The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.71","spread":"8.70"},{"groupId":"OG001","value":"-2.44","spread":"14.22"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Apolipoprotein A1 at Baseline and at the Primary Efficacy Time Point","description":"The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"146.1","spread":"24.9"},{"groupId":"OG001","value":"150.7","spread":"28.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"151.5","spread":"29.1"},{"groupId":"OG001","value":"145.4","spread":"27.9"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in High-Density Lipoprotein Cholesterol at the Primary Efficacy Time Point","description":"High-density lipoprotein cholesterol (HDL-C) was measured in mg/dL. Samples were taken following an overnight fast. The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":"9.57"},{"groupId":"OG001","value":"2.5","spread":"18.04"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"High-Density Lipoprotein Cholesterol at Baseline and at the Primary Efficacy Time Point","description":"The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":"11.1"},{"groupId":"OG001","value":"47","spread":"13.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":"13.5"},{"groupId":"OG001","value":"48","spread":"15.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":41},"commonTop":["Injection site pain","Injection site erythema","Injection site haematoma","Fatigue","Injection site pruritus"]}}}